Amalgamated Bank Trims Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Amalgamated Bank cut its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 5.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 19,872 shares of the life sciences company’s stock after selling 1,082 shares during the period. Amalgamated Bank’s holdings in Integra LifeSciences were worth $361,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of IART. Blue Trust Inc. boosted its stake in Integra LifeSciences by 100.5% during the second quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock valued at $26,000 after buying an additional 444 shares during the period. CWM LLC raised its holdings in shares of Integra LifeSciences by 50.8% in the 2nd quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock valued at $37,000 after acquiring an additional 425 shares in the last quarter. Northwest Investment Counselors LLC bought a new stake in shares of Integra LifeSciences during the 3rd quarter valued at about $73,000. Canada Pension Plan Investment Board purchased a new position in shares of Integra LifeSciences during the second quarter worth about $114,000. Finally, Allspring Global Investments Holdings LLC increased its position in shares of Integra LifeSciences by 58.0% in the second quarter. Allspring Global Investments Holdings LLC now owns 4,662 shares of the life sciences company’s stock worth $136,000 after purchasing an additional 1,711 shares during the last quarter. 84.78% of the stock is owned by hedge funds and other institutional investors.

Integra LifeSciences Stock Down 1.7 %

IART opened at $22.88 on Monday. Integra LifeSciences Holdings Co. has a 12 month low of $16.81 and a 12 month high of $45.42. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. The business’s 50-day moving average price is $19.54 and its 200-day moving average price is $24.14. The company has a market cap of $1.77 billion, a P/E ratio of -254.19, a P/E/G ratio of 0.78 and a beta of 1.08.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.02. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm had revenue of $380.80 million during the quarter, compared to the consensus estimate of $375.81 million. During the same quarter in the previous year, the company posted $0.76 earnings per share. The business’s revenue was down .4% on a year-over-year basis. On average, equities analysts expect that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have commented on IART shares. JMP Securities cut their price target on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a research note on Tuesday, July 30th. BTIG Research upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a research report on Monday, October 7th. Citigroup raised their price target on Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a research report on Tuesday, November 5th. Bank of America cut their price objective on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a report on Monday, October 7th. Finally, Truist Financial decreased their price objective on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a report on Monday, October 14th. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company. According to MarketBeat, Integra LifeSciences currently has a consensus rating of “Hold” and a consensus price target of $24.00.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.